Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Notice Release of Report for Q3 2018

2018-11-16 Please note that the report for the third quarter ended September 30, 2018 will be released on the 26th of November, 2018 at 9:00 am CET.An international conference call for investors and analysts will be held on November 28, 2018 at 3:00 pm CET. The dial-in number is: Standard International Access +44 (0) 20 3003 2666 Stockholm +46 (0) 8 50520424 New York +1 646 843 4608 Washington DC Local number +1 202 204 1514 The meeting code is Corral Q3. For further information, please contact:Magdalena PatrónInvestor Relations ManagerTel: + 46 (0)10 450 10 00

DreamHack Leipzig lowers expo age restriction to 12 years and above

Flashing screens, thrilling events, and an exciting atmosphere – from 15 to 17 February 2019, DreamHack Leipzig is the gaming community’s Mecca once again. Visitors can expect a varied three-day program of eSports tournaments, cosplay, community stars, and a large DreamExpo. As of 2019, the latter will also be of interest to young gamers. While admission was previously restricted to guests 16 years and older, this year – thanks to the development of a new hall concept – visitors 12 years and older can also attend the exhibition. “The DreamHack Leipzig is now open to visitors aged

Citi Launches Direct Custody and Clearing Services in Norway

Launch consolidates Citi’s leadership with the industry’s largest proprietary custody network in the region and globally. Opening highlights commitment to the Nordics as Citi celebrates its 45th Anniversary in Norway. Oslo, London – Citi will begin offering Direct Custody & Clearing (DCC) services to clients in Norway, starting mid-November.  The new offering expands Citi’s proprietary DCC network to over 60 markets globally including 37 markets across Europe, the Middle East and Africa (EMEA).DCC plays an integral role in the capital markets by providing clearing and settlement services

Exercise period for BrainCool’s warrants, TO1, 21 November – 4 December 2018

As part of our financing strategy and the agreement with L1 Capital, BrainCool has distributed free warrants to the company's shareholders to reduce dilution. During the period of November 21 to December 4, 2018, holders of TO1 Warrants can exercise the Warrants and subscribe for new shares. One (1) TO1 warrant can be exchanged for one (1) share, at a price of SEK 13.93. The current market price is below the exercise price. Unless the market price exceeds the exercise price, it is not beneficial to subscribe in the current exercise period. Therefore, the application form has not been

Interim report January – September 2018

Third quarter in brief · SyntheticMRs had sales growth of 46% in the third quarter compared to the previous year. · Net sales amounted to SEK 11,2 million (7,7) · Operating profit increased to SEK 5,4 million (2,2) · Profit for the period amounted to SEK 4,2 million (1,7) · Earnings per share amounted to SEK 1,04 (0,42) · Sales for rolling 12 months amounted to SEK 46,1 million (31,6) Nine months in brief · Net sales amounted to SEK 33,0 M (22,5), which means sales growth of 47% · Operating profit increased to SEK 13,4 M (5,7) · Profit for the period amounted

The University Hospital, Vejle Hospital and 2cureX have received approval to start a clinical trial in pancreatic cancer

2cureX AB (“2cureX”) is pleased to announce that we together with our clinical partner Vejle Hospital have received approval to launch a clinical trial in metastatic pancreatic cancer. Patients will be included in the trial from November 2018 to December 2020. Patient outcome data will be collected until December 2023. The study is an investigator-initiated trial where costs are shared between the hospital and 2cureX. IndiTreat® is now being clinically validated in three major cancer diseases (colorectal, ovarian and pancreatic cancers).Pancreatic cancer is globally one of the most common

ChromoGenics delivers I-Window glass to Kungsleden for an order value of approximately SEK 275 thousand

ChromoGenics AB (publ) has signed an agreement with Kungsleden to deliver I-Window glass to Kvartersakuten Mörby in Stockholm for a retro-fit project where existing glass is replaced with maintenance-free I-Window glass.The project is a retro-fit project of about 60 sqm I-Window glass including construction work with planned delivery in the fourth quarter of 2018. Kungsleden chose to upgrade the property's windows to maintenance-free I-Window glass instead of traditional outside solar control systems. In the premises, a healthcare center conducts its activities. "We are proud that

Sabine Helterhoff appointed new BU President for Bonava Germany

Sabine Helterhoff is appointed President of Business Unit Bonava Germany. Sabine Helterhoff is currently Head of Legal and Investor Business for Bonava Germany. Sabine will take up the new position on 1 January 2019, she succeeds Olle Boback who will be retiring.- It pleases me that we now have appointed a new BU President for Bonava Germany. With Sabine Helterhoff’s broad knowledge within the housing developer industry and her 18 years in the company as Head of Legal and Investor Business in Germany, Sabine Helterhoff will make an excellent successor to Olle Boback, says Joachim Hallengren,

Jays announces partnership with Emart in South Korea

Jays branded fixture at Emart flagshipstore in Yeongdeungpo [Jag tror vi behöver en bra bas i Sydkorea. Vi får denna chansen] Jag tror vi behöver en bra bas i Sydkorea. Vi får denna chansen Jays announces partnership with Emart in South Korea  General Press releaseSwedish audio product developer Jays Group AB (publ) is partnering with Emart, leading technology retailer with 148 stores in South Korea. Jays Group AB (publ) announces a new partnership in South Korea together with Emart. The cooperation which started in Q4 2018 involves Jays full range of products in 30 APRs (

Dignitana AB (Publ) Announces Rights Issue and Directed Equity Issue

Dignitana AB to carry out new issues of approximately SEK 31.6M in a directed issue of approximately SEK 5.8M, a fully guaranteed rights issue of SEK 24.3M with preferential right for existing shareholders and another directed rights issue offsetting the guarantee fee of approximately SEK 1.4M.The Board of Directors of Dignitana AB (“Dignitana” or the “Company”) decided today to carry out a capitalization of up to SEK 31.6M in a directed rights issue of approximately SEK 5.8M, a fully guaranteed rights issue of SEK 24.3M with preferential right for existing shareholders and another directed

AstraZeneca provides update on Phase III MYSTIC

This announcement contains inside information 16 November 2018 07:00 GMT AstraZeneca provides update on the Phase III MYSTIC trial of Imfinzi and tremelimumab in Stage IV non-small cell lung cancer AstraZeneca and MedImmune, its global biologics research and development arm, today announced final overall survival (OS) results for the Phase III MYSTIC trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) monotherapy and the combination of Imfinziand tremelimumab, an anti-CTLA4 antibody, versus standard-of-care (SoC) platinum-based chemotherapy in

Last day of trading in subscription rights

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES (OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL).Reference is made to previous announcements in respect of the Rights Issue of up to 17,391,304 new shares in Nordic Mining ASA. The period for trading in subscription rights (ticker "NOM T") for the Rights Issue will expire today, Friday 16 November 2018 at 16:30 (CET). Subscription rights for participation in the Rights Issue can be exercised during the

Annual General Meeting 2019 and information about appointed members to the Nomination Committee

The 2019 Annual General Meeting (AGM) of Nexam Chemical Holding AB (publ) will be held on Thursday, 16 May 2019, at 3:00 pm, at Elite Hotel Ideon, Scheelevägen 27 in Lund, Sweden.Shareholders are entitled to have items put on the agenda for the Annual General Meeting, if a request has been received by the Board of Directors no later than 28 March 2019. The Board of Directors can be contacted via email at: styrelsen@nexamchemical.com or by regular mail addressed to: Nexam Chemical Holding AB (publ), Att: Board of Directors Box 165, 234 23 LOMMA, Sweden. At the Annual General Meeting May

Raketech launches Esportsguide.com to target the global Esports community

Raketech today announced the launch of a new product targeting the popular Esports community. Esportsguide.com will provide a complete guide to the leading Esports streams for the most popular tournaments from across the globe.Michael Holmberg, Raketech CEO said: “Raketech is entering the popular Esports industry, launching a global product with a strong US market appeal. Esportsguide.com is an adaptation of our TV sports guide product and another example of scalability within our product strategy – entering new markets or verticals with existing platforms. We believe there is a gap in the

MARKETING TERRITORY FOR VIRUSEPTIN® EXTENDED TO INCLUDE DENMARK

STOCKHOLM  16 November 2018· Karo Pharma AB extends the marketing territory for Viruseptin® to include Denmark and have with this the marketing rights across the Nordic countries. · The product is patent protected and is very well documented with 5 clinical trials in which more than 600 adults and children were included. It has shown good effect for the treatment of common cold and flu like symptoms in connection with viral infections in the nose and throat. FOR FURTHER INFORMATION PLEASE CONTACT:Peter Blom, CEO, 070-655 56 98 or peter.blom@karopharma.se ABOUT KARO PHARMAKaro

Humana reports third quarter results 2018

A strong quarter with better profitability and increased growth Third quarter July-September 2018 in brief:  ·  Operating revenue was SEK 1 677 M (1 613), an increase of 4%. Adjusted for the divested home care service business, which contributed to revenue last year, revenue increased by 7 %. ·  Operating profit was SEK 151 M (SEK 110 M incl. SEK 14 M in capital loss), an increase of 37 % or SEK 41 M. ·  Net profit after tax for the period was SEK 102 M (71). ·  Earnings per share for the period before and after dilution were SEK 1.92 (1.34). ·  Operating cash flow was

Strong sales and earnings growth

The third quarter: July – September · Net sales of SEK 237.7 (206.0) million, an increase of 15.3 percent or SEK 31.7 million. · Order intake of SEK 127.4 (202.2) million, a decrease of 37.0 percent · Order backlog decreased by SEK 106.1 million, equivalent to 8.1 percent to SEK 1,202.7 million at the end of the quarter · Operating profit of SEK 25.1 (12.2) million, an increase of 106 percent. · Net profit after tax of SEK 19.1 (-2.0) million, an increase of SEK 21.1 million. · Earnings per ordinary share of SEK 0.89 (-0.48), before and after dilution. · Operating

Essity awarded for innovation and sustainability

Essity has won the awards ‘Technical Innovation of the Year’ for Tork EasyCube® and ‘Best Practice - Sustainability’ at the 2018 European Cleaning & Hygiene Awards. The awards were announced on November 15 in Berlin.[Tork PaperCircle] New connectivity, customer insights and proven customer value convinced the jury to see Essity’s Tork EasyCube as an innovation that just keeps innovating. Tork EasyCube®, launched in 2014, is the world’s leading facility management software for data-driven cleaning. Sensors in facilities measuring visitor traffic and refill levels allow facility managers

Dignitana AB Publishes Q3 Interim Report

Results and financial position Significant events during the period · Sales for the period amounted to 10,293 TSEK, $1,150 KUSD, an increase of 125 percent compared to the same period in 2017 and an increase of 14 percent compared to the second quarter 2018. · EBITDA amounted to (3,459) TSEK, ($386 KUSD), a 56 percent improvement compared to the same period in 2017. · 6 units were sold to facilities in countries outside the U.S. · Contracts for 7 locations in the U.S. were signed. · Third quarter treatment revenue in the U.S. increased over second quarter 2018. · In

Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors

GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the appointment of Robert Marchesani as an advisor to its board of directors. Mr. Marchesani has nearly 30 years of experience in the life science industry, leading a variety of business activities including product development, global branding and marketing with a particular focus on oncology.Mr. Marchesani commented, “I am delighted to be joining Isofol’s team of advisors as it prepares for the initiation of its global Phase 3 clinical study of arfolitixorin. I look

Sivers IMA Interim Report January–September 2018, a strong quarter with two new 5G customers and clearly improved EBITDA result compared to both 2017 and the 2nd quarter 2018.

Third quarter 2018 · Operating income for the period amounted to SEK 34,624 thousand (24,752), an increase of 40 percent · Net sales for the period amounted to SEK 25,217 thousand (15,016), an increase of 68 percent · Earnings before depreciation (EBITDA) for the period amounted to SEK -3,301 thousand (-10,508) · Result for the period amounted to SEK -19,276 thousand (-22,031) · Earnings per share amounted to SEK -0.17 (-0.22) · Equity per share amounted to SEK 2.09 (2.24)January–September 2018 · Operating income for the period amounted to SEK 82,695 thousand (53,

Scan Global Logistics acquires German IQS Group, the leading automobile logistics specialist

Scan Global Logistics A/S today announce that it has acquired 100% ownership of the leading special solution provider for high-end automotive logistics – German based, International Quality Service Group (IQS Group). “This acquisition is a natural strategic step forward in the ongoing growth and development of Scan Global Logistics internationally. IQS Group is a perfect fit in our strategy and enables us to take a position as one of the leading companies in the automotive industry. Germany is probably the number one country in the world in terms of high-end car manufacturers - many of

Recipharm CEO sells shares - remains committed and significant holder

Thomas Eldered, CEO and co-founder of Recipharm AB, has informed the Company that he has sold 1,559,125 Class B shares in Recipharm, representing approximately 12.7% of his total shareholding in the Company, to a Swedish institutional investor. Following the transaction, Thomas Eldered remains the single largest shareholder in Recipharm and holds 15.8% of the shares and 38.7% of the votes in the Company. Thomas commented: “There are only personal financial reasons behind the decision to sell a small portion of my shares in Recipharm. I have no intention to sell any additional shares in

There are no items matching the current filter
There are no more items matching the current filter
Back to top